**Supplementary Table 3.** Quartiles of WC and BMI variability measures and risk of neuropathy after excluding those who developed neuropathic event in the first year and those who had serious adverse events in first 18 months of the study

| Variable   | Events | Incidence rate/10 person-yr | Model 1 | Model 2<sup>1</sup> |
|------------|--------|----------------------------|---------|---------------------|
|            |        |                            | HR (95% CI) | P value | HR (95% CI) | P value |
| WC (cVIM)  |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 485    | 0.9                         | Ref      |         | Ref         |         |
| Q2         | 623    | 1.1                         | 1.26 (1.09–1.45) | 0.001  | 1.25 (1.09–1.45) | 0.002  |
| Q3         | 672    | 1.3                         | 1.40 (1.16–1.70) | 0.001  | 1.42 (1.15–1.71) | 0.001  |
| Q4         | 677    | 1.3                         | 1.43 (1.10–1.85) | 0.008  | 1.44 (1.10–1.88) | 0.007  |
| WC (ASV)   |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 502    | 0.9                         | Ref      |         | Ref         |         |
| Q2         | 655    | 1.2                         | 1.33 (1.16–1.53) | <0.001 | 1.31 (1.14–1.51) | <0.001 |
| Q3         | 625    | 1.1                         | 1.26 (1.03–1.53) | 0.022  | 1.21 (0.99–1.47) | 0.064  |
| Q4         | 675    | 1.3                         | 1.43 (1.12–1.87) | 0.005  | 1.39 (1.07–1.81) | 0.015  |
| WC (CV)    |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 483    | 0.9                         | Ref      |         | Ref         |         |
| Q2         | 630    | 1.1                         | 1.29 (1.12–1.48) | <0.001 | 1.28 (1.11–1.48) | 0.001  |
| Q3         | 666    | 1.2                         | 1.41 (1.16–1.71) | 0.001  | 1.41 (1.16–1.72) | 0.001  |
| Q4         | 678    | 1.3                         | 1.46 (1.12–1.90) | 0.005  | 1.47 (1.12–1.91) | 0.005  |
| WC (SD)    |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 464    | 0.8                         | Ref      |         | Ref         |         |
| Q2         | 626    | 1.1                         | 1.40 (1.21–1.61) | <0.001 | 1.36 (1.17–1.57) | <0.001 |
| Q3         | 672    | 1.3                         | 1.57 (1.29–1.91) | <0.001 | 1.51 (1.24–1.85) | <0.001 |
| Q4         | 695    | 1.3                         | 1.71 (1.31–2.22) | <0.001 | 1.63 (1.25–2.13) | <0.001 |
| BMI (cVIM) |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 545    | 1.0                         | Ref      |         | Ref         |         |
| Q2         | 601    | 1.1                         | 1.11 (0.97–1.28) | 0.130  | 1.14 (0.99–1.31) | 0.067  |
| Q3         | 647    | 1.2                         | 1.23 (1.02–1.49) | 0.033  | 1.26 (1.04–1.52) | 0.020  |
| Q4         | 664    | 1.2                         | 1.30 (1.00–1.67) | 0.047  | 1.36 (1.05–1.77) | 0.019  |
| BMI (ASV)  |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 558    | 1.0                         | Ref      |         | Ref         |         |
| Q2         | 617    | 1.1                         | 1.17 (1.02–1.34) | 0.030  | 1.15 (1.00–1.32) | 0.052  |
| Q3         | 637    | 1.2                         | 1.25 (1.03–1.51) | 0.023  | 1.22 (1.00–1.48) | 0.049  |
| Q4         | 645    | 1.2                         | 1.36 (1.05–1.76) | 0.018  | 1.31 (1.01–1.71) | 0.041  |
| BMI (CV)   |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 535    | 1.0                         | Ref      |         | Ref         |         |
| Q2         | 605    | 1.1                         | 1.17 (1.02–1.35) | 0.024  | 1.18 (1.03–1.36) | 0.018  |
| Q3         | 633    | 1.2                         | 1.29 (1.06–1.56) | 0.010  | 1.29 (1.06–1.57) | 0.010  |
| Q4         | 684    | 1.3                         | 1.48 (1.15–1.91) | 0.002  | 1.51 (1.16–1.95) | 0.002  |
| BMI (SD)   |        |                             | HR (95% CI) | P value | HR (95% CI) | P value |
| Q1         | 509    | 0.9                         | Ref      |         | Ref         |         |
| Q2         | 607    | 1.1                         | 1.22 (1.06–1.40) | 0.006  | 1.22 (1.05–1.40) | 0.007  |
| Q3         | 653    | 1.2                         | 1.34 (1.11–1.63) | 0.003  | 1.33 (1.09–1.62) | 0.004  |
| Q4         | 688    | 1.3                         | 1.47 (1.13–1.90) | 0.004  | 1.48 (1.14–1.93) | 0.004  |

Model 1: unadjusted model; Model 2<sup>1</sup>: Adjusted for age, sex, race, duration of diabetes, allocation to glycemia treatment arm, blood pressure (BP) vs. lipid treatment arm, systolic BP, diastolic BP, low density lipoprotein, high density lipoprotein, glycosylated hemoglobin, insulin use, alcohol consumption, and baseline BMI (or WC).

WC, waist circumference; BMI, body mass index; HR, hazard ratio; CI, confidence interval; cVIM, corrected variability independent of mean; ASV, average successive variability; CV, coefficient of variation; SD, standard deviation.

https://e-dmj.org Diabetes Metab J 2022;46:767-780